1 ANNEX, Regulation (EU) 2016/1179

In forcesince 19 Jul 2016

Table 3.1 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows:

(a)

the entries corresponding to index numbers 607-331-00-5 and 609-066-00-0 are deleted;

(b)

the entries corresponding to index numbers, 006-035-00-8, 029-002-00-X, 602-020-00-0, 602-033-00-1, 603-055-00-4, 604-030-00-0, 604-092-00-9, 605-013-00-0, 605-022-00-X, 606-014-00-9, 606-021-00-7, 607-056-00-0, 607-059-00-7, 607-157-00-X, 607-172-00-1, 607-375-00-5, 607-623-00-2, 613-166-00-X, 613-121-00-4, 616-011-00-4, 616-037-00-6 and 616-207-00-X are replaced by the following entries respectively:

Index No | International Chemical Identification | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors | Notes

Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s)

‘006-035-00-8 | pirimicarb (ISO); 2-(dimethylamino)-5,6-dimethylpyrimidin-4-yl dimethylcarbamate | 245-430-1 | 23103-98-2 |

Carc. 2

Acute Tox. 3

Acute Tox. 3

Skin Sens. 1

Aquatic Acute 1 Aquatic Chronic 1

H351

H331

H301

H317

H400

H410

GHS08

GHS06

GHS09

Dgr

H351

H331

H301

H317

H410

M = 10

M = 100’

‘029-002-00-X |

dicopper oxide;

copper (I) oxide

215-270-7 | 1317-39-1 |

Acute Tox. 4

Acute Tox. 4

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H332

H302

H318

H400

H410

GHS07

GHS05

GHS09

Dgr

H332

H302

H318

H410

M = 100’ |

‘602-020-00-0 |

1,2-dichloropropane;

propylene dichloride

201-152-2 | 78-87-5 |

Flam. Liq. 2

Carc. 1B

Acute Tox. 4*

Acute Tox. 4*

H225

H350

H332

H302

GHS02

GHS08

GHS07

Dgr

H225

H350

H332

H302’

‘602-033-00-1 | chlorobenzene | 203-628-5 | 108-90-7 |

Flam. Liq. 3

Acute Tox. 4

Skin Irrit. 2

Aquatic Chronic 2

H226

H332

H315

H411

GHS02

GHS07

GHS09

Wng

H226

H332

H315

H411’

‘603-055-00-4 |

propylene oxide;

1,2-epoxypropane; methyloxirane

200-879-2 | 75-56-9 |

Flam. Liq. 1

Carc. 1B

Muta. 1B

Acute Tox. 3

Acute Tox. 3

Acute Tox. 4

STOT SE 3

Eye Irrit. 2

H224

H350

H340

H331

H311

H302

H335

H319

GHS02

GHS08

GHS06

Dgr

H224

H350

H340

H331

H311

H302

H335

H319’

‘604-030-00-0 |

bisphenol A;

4,4′-isopropylidenediphenol

201-245-8 | 80-05-7 |

Repr. 1B

STOT SE 3

Eye Dam. 1

Skin Sens. 1

H360F

H335

H318

H317

GHS08

GHS05 GHS07

Dgr

H360F

H335

H318

H317’

‘604-092-00-9 |

phenol, dodecyl-, branched; [1]

phenol, 2-dodecyl-, branched; [2]

phenol, 3-dodecyl-, branched; [3]

phenol, 4-dodecyl-, branched; [4]

phenol, (tetrapropenyl) derivatives [5]

310-154-3 [1]

[2]

[3]

[4]

[5]

121158-58-5 [1]

[2]

[3]

210555-94-5 [4]

74499-35-7 [5]

Repr. 1B

Skin Corr. 1C

Eye Dam. 1

Aquatic Acute 1 Aquatic Chronic 1

H360F

H314

H318

H400

H410

GHS08

GHS05

GHS09

Dgr

H360F

H314

H410

M = 10

M = 10’

‘605-013-00-0 |

chloralose (INN);

(R)-1,2-O-(2,2,2-trichloroethylidene)-α-D-glucofuranose; glucochloralose; anhydroglucochloral

240-016-7 | 15879-93-3 |

Acute Tox. 4*

Acute Tox. 3

STOT SE 3

Aquatic Acute 1

Aquatic Chronic 1

H332

H301

H336

H400

H410

GHS06

GHS09

Dgr

H332

H301

H336

H410

M = 10

M = 10

C’

‘605-022-00-X |

glutaral; glutaraldehyde;

1,5-pentanedial

203-856-5 | 111-30-8 |

Acute Tox. 2

Acute Tox. 3

STOT SE 3

Skin Corr. 1B

Resp. Sens. 1

Skin Sens. 1A

Aquatic Acute 1

Aquatic Chronic 2

H330

H301

H335

H314

H334

H317

H400

H411

GHS06

GHS05

GHS08

GHS09

Dgr

H330

H301

H335

H314

H334

H317

H410

EUH071 |

STOT SE 3; H335: 0,5 % ≤ C < 5 %

M = 1’

‘606-014-00-9 |

chlorophacinone (ISO);

2-[(4-chlorophenyl)(phenyl)acetyl]-1H-indene-1,3(2H)-dione

223-003-0 | 3691-35-8 |

Repr. 1B

Acute Tox. 1

Acute Tox. 1

Acute Tox. 1

STOT RE 1

Aquatic Acute 1

Aquatic Chronic 1

H360D

H330

H310

H300

H372 (blood)

H400

H410

GHS08

GHS06

GHS09

Dgr

H360D

H330

H310

H300

H372 (blood)

H410

Repr. 1B; H360D:

C ≥ 0,003 %

STOT RE 1; H372 (blood): C ≥ 0,1 %

STOT RE 2; H373 (blood):

0,01 % ≤ C < 0,1 %

M = 1

M = 1’

‘606-021-00-7 | N-methyl-2-pyrrolidone; 1-methyl-2-pyrrolidone | 212-828-1 | 872-50-4 |

Repr. 1B

STOT SE 3

Skin Irrit. 2

Eye Irrit. 2

H360D***

H335

H315

H319

GHS08

GHS07

Dgr

H360D***

H335

H315

H319

STOT SE 3; H335: C ≥ 10 %’ |

‘607-056-00-0 |

warfarin (ISO);

4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one; [1]

(S)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone; [2]

(R)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone [3]

201-377-6

[1]

226-907-3

[2]

226-908-9

[3]

81-81-2 [1]

5543-57-7

[2]

5543-58-8

[3]

Repr. 1A

Acute Tox. 1

Acute Tox. 1

Acute Tox. 2

STOT RE 1

Aquatic Chronic 2

H360D

H330

H310

H300

H372 (blood)

H411

GHS08

GHS06

GHS09

Dgr

H360D

H330

H310

H300

H372 (blood)

H411

Repr. 1A; H360D:

C ≥ 0,003 %

STOT RE 1; H372 (blood): C ≥ 0,5 %

STOT RE 2; H373 (blood): 0,05 % ≤ C < 0,5 %’

‘607-059-00-7 | coumatetralyl (ISO); 4-hydroxy-3-(1,2,3,4-tetrahydro-1-naphthyl)coumarin | 227-424-0 | 5836-29-3 |

Repr. 1B

Acute Tox. 2

Acute Tox. 3

Acute Tox. 2

STOT RE 1

Aquatic Chronic 1

H360D

H330

H311

H300

H372 (blood)

H410

GHS08

GHS06

GHS09

Dgr

H360D

H330

H311

H300

H372 (blood)

H410

Repr. 1B; H360D: C ≥ 0,003 %

STOT RE 1; H372 (blood): C ≥ 1,0 %

STOT RE 2; H373 (blood) 0,1 % ≤ C < 1,0 %

M = 10’

‘607-157-00-X | difenacoum (ISO); 3-(3-biphenyl-4-yl-1,2,3,4-tetrahydro-1-naphthyl)-4-hydroxycoumarin | 259-978-4 | 56073-07-5 |

Repr. 1B

Acute Tox. 1

Acute Tox. 1

Acute Tox. 1

STOT RE 1

Aquatic Acute 1

Aquatic Chronic 1

H360D

H330

H310

H300

H372 (blood)

H400

H410

GHS08

GHS06

GHS09

Dgr

H360D

H330

H310

H300

H372 (blood)

H410

Repr. 1B; H360D:

C ≥ 0,003 %

STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood):

0,002 % ≤ C < 0,02 %

M = 10

M = 10’

‘607-172-00-1 |

brodifacoum (ISO);

4-hydroxy-3-(3-(4′-bromo-4-biphenylyl)-1,2,3,4-tetrahydro-1-naphthyl)coumarin

259-980-5 | 56073-10-0 |

Repr. 1A

Acute Tox. 1

Acute Tox. 1

Acute Tox. 1

STOT RE 1

Aquatic Acute 1

Aquatic Chronic 1

H360D

H330

H310

H300

H372 (blood)

H400

H410

GHS08

GHS06

GHS09

Dgr

H360D

H330

H310

H300

H372 (blood)

H410

Repr. 1A; H360D:

C ≥ 0,003 %

STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood):

0,002 % ≤ C < 0,02 %

M = 10

M = 10’

‘607-375-00-5 | flocoumafen (ISO); reaction mass of: cis-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin and trans-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin | 421-960-0 | 90035-08-8 |

Repr. 1B

Acute Tox. 1

Acute Tox. 1

Acute Tox. 1

STOT RE 1

Aquatic Acute 1

Aquatic Chronic 1

H360D

H330

H310

H300

H372 (blood)

H400

H410

GHS08

GHS06

GHS09

Dgr

H360D

H330

H310

H300

H372 (blood)

H410

Repr. 1B; H360D:

C ≥ 0,003 %

STOT RE 1; H372 (blood): C ≥ 0,05 %

STOT RE 2; H373 (blood):

0,005 % ≤ C < 0,05 %

M = 10

M = 10’

‘607-623-00-2 | diisobutyl phthalate | 201-553-2 | 84-69-5 | Repr. 1B | H360Df |

GHS08

Dgr

H360Df’ | | |

‘613-166-00-X |

flumioxazin (ISO);

2-[7-fluoro-3-oxo-4-(prop-2-yn-1-yl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione

–

| 103361-09-7 |

Repr. 1B

Aquatic Acute 1

Aquatic Chronic 1

H360D

H400

H410

GHS08

GHS09

Dgr

H360D

H410

M = 1000

M = 1000’

‘613-121-00-4 | chlorsulfuron (ISO); 2-chloro-N-[[(4-methoxy-6-methyl-1,3,5-triazin-2- yl)amino]carbonyl]benzenesulphonamide | 265-268-5 | 64902-72-3 |

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410 | |

M = 1000

M = 100’

‘616-011-00-4 | N,N-dimethylacetamide | 204-826-4 | 127-19-5 |

Repr. 1B

Acute Tox. 4*

Acute Tox. 4*

H360D***

H332

H312

GHS08

GHS07

Dgr

H360D***

H332

H312’

‘616-037-00-6 | acetochlor (ISO); 2-chloro-N-(ethoxymethyl)-N-(2-ethyl-6-methylphenyl)acetamide | 251-899-3 | 34256-82-1 |

Carc. 2

Repr. 2

Acute Tox. 4

STOT SE 3

STOT RE 2

Skin Irrit. 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H351

H361f

H332

H335

H373 (kidney)

H315

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H361f

H332

H335

H373 (kidney)

H315

H317

H410

M = 1000

M = 100’

‘616-207-00-X |

polyhexamethylene biguanide hydrochloride;

PHMB

–

|

32289-58-0

27083-27-8

Carc. 2

Acute Tox. 2

Acute Tox. 4

STOT RE 1

Eye Dam. 1

Skin Sens. 1B

Aquatic Acute 1

Aquatic Chronic 1

H351

H330

H302

H372 (respiratory tract) (inhalation)

H318

H317

H400

H410

GHS08

GHS06

GHS05

GHS09

Dgr

H351

H330

H302

H372 (respiratory tract) (inhalation)

H318

H317

H410

M = 10

M = 10’

(c)

the following entries are inserted in accordance with the order of the index numbers:

Index No | International Chemical Identification | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors | Notes

Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s)

‘005-020-00-3 |

disodium octaborate anhydrous; [1]

disodium octaborate tetrahydrate [2]

234-541-0 [1]

234-541-0 [2]

12008-41-2 [1]

12280-03-4 [2]

Repr. 1B | H360FD |

GHS08

Dgr

H360FD’ | | |

‘014-046-00-4 | e-glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following representative composition (% given by weight): SiO2 50,0-56,0 %, Al2O3 13,0-16,0 %, B2O3 5,8-10,0 %, Na2O < 0,6 %, K2O < 0,4 %, CaO 15,0-24,0 %, MgO < 5,5 %, Fe2O3 < 0,5 %, F2 < 1,0 %. Process: typically produced by flame attenuation and rotary process. (Additional individual elements may be present at low levels; the process list does not preclude innovation).] | — | — | Carc. 1B | H350i |

GHS08

Dgr

H350i | | | A’

‘014-047-00-X | glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following composition (% given by weight): SiO2 55,0-60,0 %, Al2O3 4,0-7,0 %, B2O3 8,0-11,0 %, ZrO2 0,0-4,0 %, Na2O 9,5-13,5 %, K2O 0,0-4,0 %, CaO 1,0-5,0 %, MgO 0,0-2,0 %, Fe2O3 < 0,2 %, ZnO 2,0-5,0 %, BaO 3,0-6,0 %, F2 < 1,0 %. Process: typically produced by flame attenuation and rotary process. (Additional individual elements may be present at low levels; the process list does not preclude innovation).] | — | — | Carc. 2 | H351 (inhalation) |

GHS08

Wng

H351 (inhalation) | | | A’

‘029-015-00-0 | copper thiocyanate | 214-183-1 | 1111-67-7 | Aquatic Acute 1 Aquatic Chronic 1 |

H400

H410

GHS09

Wng

H410 | EUH032 | M = 10’ |

‘029-016-00-6 | copper(II) oxide | 215-269-1 | 1317-38-0 |

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410 | | M = 100’ |

‘029-017-00-1 | dicopper chloride trihydroxide | 215-572-9 | 1332-65-6 |

Acute Tox. 4

Acute Tox. 3

Aquatic Acute 1

Aquatic Chronic 1

H332

H301

H400

H410

GHS06

GHS09

Dgr

H332

H301

H410

M = 10’ |

‘029-018-00-7 |

tetracopper hexahydroxide sulphate; [1]

tetracopper hexahydroxide sulphate hydrate [2]

215-582-3 [1]

215-582-3 [2]

1333-22-8 [1]

12527-76-3 [2]

Acute Tox. 4

Aquatic Acute 1 Aquatic Chronic 1

H302

H400

H410

GHS07

GHS09

Wng

H302

H410

M = 10’ |

‘029-019-01-X | copper flakes (coated with aliphatic acid) | — | — |

Acute Tox. 3

Acute Tox. 4

Eye Irrit. 2

Aquatic Acute 1

Aquatic Chronic 1

H331

H302

H319

H400

H410

GHS06

GHS09

Dgr

H331

H302

H319

H410

M = 10’ |

‘029-020-00-8 | copper(II) carbonate--copper(II) hydroxide (1:1) | 235-113-6 | 12069-69-1 |

Acute Tox. 4

Acute Tox. 4

Eye Irrit. 2

Aquatic Acute 1

Aquatic Chronic 1

H332

H302

H319

H400

H410

GHS07

GHS09

Wng

H332

H302

H319

H410

M = 10’ |

‘029-021-00-3 |

copper dihydroxide;

copper(II) hydroxide

243-815-9 | 20427-59-2 |

Acute Tox. 2

Acute Tox. 4

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H330

H302

H318

H400

H410

GHS06

GHS05

GHS09

Dgr

H330

H302

H318

H410

M = 10’ |

‘029-022-00-9 |

bordeaux mixture;

reaction products of copper sulphate with calcium dihydroxide

–

| 8011-63-0 |

Acute Tox. 4

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H332

H318

H400

H410

GHS07

GHS05

GHS09

Dgr

H332

H318

H410

M = 10’ |

‘029-023-00-4 | copper sulphate pentahydrate | 231-847-6 | 7758-99-8 |

Acute Tox. 4

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H302

H318

H400

H410

GHS07

GHS05

GHS09

Dgr

H302

H318

H410

M = 10’ |

‘082-013-00-1 |

lead powder;

[particle diameter < 1 mm]

231-100-4 | 7439-92-1 |

Repr. 1A

Lact.

H360FD

H362

GHS08

Dgr

H360FD

H362

Repr. 1A; H360D: C ≥ 0,03 %’ |

‘082-014-00-7 |

lead massive:

[particle diameter ≥ 1 mm]

231-100-4 | 7439-92-1 |

Repr. 1A

Lact.

H360FD

H362

GHS08

Dgr

H360FD

H362’

‘605-040-00-8 |

hydroxyisohexyl 3-cyclohexene carboxaldehyde (INCI); reaction mass of 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde and 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; [1]

4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; [2]

3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde [3]

–

[1]

250-863-4 [2]

257-187-9 [3]

130066-44-3 [1]

31906-04-4 [2]

51414-25-6 [3]

Skin Sens. 1A | H317 |

GHS07

Wng

H317’ | | |

‘607-716-00-8 | bromadiolone (ISO); 3-[3-(4′-bromobiphenyl-4-yl)-3-hydroxy-1-phenylpropyl]-4-hydroxy-2H-chromen-2-one | 249-205-9 | 28772-56-7 |

Repr. 1B

Acute Tox. 1

Acute Tox. 1

Acute Tox. 1

STOT RE 1

Aquatic Acute 1

Aquatic Chronic 1

H360D

H330

H310

H300

H372 (blood)

H400

H410

GHS08

GHS06

GHS09

Dgr

H360D

H330

H310

H300

H372 (blood)

H410

Repr. 1B; H360D:

C ≥ 0,003 %

STOT RE 1; H372 (blood): C ≥ 0,005 % STOT RE 2; H373 (blood):

0,0005 % ≤ C < 0,005 %

M = 1

M = 1’

‘607-717-00-3 |

difethialone (ISO);

3-[3-(4′-bromobiphenyl-4-yl)-1,2,3,4-tetrahydronaphthalen-1-yl]-4-hydroxy-2H-1-benzothiopyran-2-one

–

| 104653-34-1 |

Repr. 1B

Acute Tox. 1

Acute Tox. 1

Acute Tox. 1

STOT RE 1

Aquatic Acute 1

Aquatic Chronic 1

H360D

H330

H310

H300

H372 (blood)

H400

H410

GHS08

GHS06

GHS09

Dgr

H360D

H330

H310

H300

H372 (blood)

H410

EUH070 |

Repr. 1B; H360D:

C ≥ 0,003 %

STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood):

0,002 % ≤ C < 0,02 %

M = 100

M = 100’

‘607-718-00-9 | perfluorononan-1-oic acid [1] and its sodium [2] and ammonium [3] salts |

206-801-3 [1]

[2]

[3]

375-95-1 [1]

21049-39-8 [2]

4149-60-4 [3]

Carc. 2

Repr. 1B

Lact.

Acute Tox. 4

Acute Tox. 4

STOT RE 1

Eye Dam. 1

H351

H360Df

H362

H332

H302

H372 (liver, thymus, spleen)

H318

GSH08

GSH07

GHS05

Dgr

H351

H360Df

H362

H332

H302

H372 (liver, thymus, spleen)

H318’

‘607-719-00-4 | dicyclohexyl phthalate | 201-545-9 | 84-61-7 |

Repr. 1B

Skin Sens. 1

H360D

H317

GHS08

GHS07

Dgr

H360D

H317’

‘608-067-00-3 | 3,7-dimethylocta-2,6-dienenitrile | 225-918-0 | 5146-66-7 | Muta. 1B | H340 |

GHS08

Dgr

H340’ | | |

‘612-288-00-0 |

bupirimate (ISO);

5-butyl-2-ethylamino-6-methylpyrimidin-4-yl dimethylsulphamate

255-391-2 | 41483-43-6 |

Carc. 2

Skin Sens. 1B

Aquatic Chronic 1

H351

H317

H410

GHS08

GHS07

GHS09

Wng

H351

H317

H410

M = 1’ |

‘612-289-00-6 |

triflumizole (ISO);

(1E)-N-[4-chloro-2-(trifluoromethyl)phenyl]-1-(1H-imidazol-1-yl)-2-propoxyethanimine

–

| 68694-11-1 |

Repr. 1B

Acute Tox. 4

STOT RE 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H360D

H302

H373 (liver)

H317

H400

H410

GHS08

GHS07

GHS09

Dgr

H360D

H302

H373 (liver)

H317

H410

M = 1

M = 1’

‘616-218-00-X | benzovindiflupyr (ISO); N-[9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide | — | 1072957-71-1 |

Acute Tox. 3

Acute Tox. 3

Aquatic Acute 1

Aquatic Chronic 1

H331

H301

H400

H410

GHS06

GHS09

Dgr

H331

H301

H410

M = 100

M = 100’

‘616-219-00-5 | fluopyram (ISO); N-{2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl}-2-(trifluoromethyl)benzamide | — | 658066-35-4 | Aquatic Chronic 2 | H411 | GHS09 | H411’ | | |

‘616-220-00-0 | pencycuron (ISO); 1-[(4-chlorophenyl)methyl]-1-cyclopentyl-3-phenylurea | 266-096-3 | 66063-05-6 |

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410 | |

M = 1

M = 1’

‘617-023-00-2 | tert-butyl hydroperoxide | 200-915-7 | 75-91-2 | Muta. 2 | H341 |

GHS08

Wng

H341’ | | |